Visão geral da empresa
A clinical-stage immuno-oncology enterprise focused on the United States market, ALX Oncology Holdings Inc. concentrates its resources on developing advanced therapeutic biologics designed to address critical needs in cancer treatment. The organization operates within the healthcare sector, specifically the biotechnology industry, where capital intensity and significant regulatory hurdles define the operational landscape for firms developing novel drug candidates. As of the latest reporting period, the company maintains a market capitalization of $223.73M and employs a workforce of 43 individuals to advance its pipeline. The market capitalization of $223.73M suggests a mid-cap positioning within the biotechnology space, while the absence of reported annual revenue indicates that the firm is currently in a pre-commercialization phase typical for clinical-stage entities.
Saúde financeira
The financial statements reveal a Net Income (TTM) of $-101,695,000 and an EBITDA of $-100,140,000, while Revenue (TTM) is not available due to the pre-revenue stage of operations. The substantial negative gap between the non-existent revenue and the significant net loss of $-101,695,000 highlights a cost structure driven entirely by research and development expenditures rather than operational overhead associated with sales. The company generated a Free Cash Flow of $-50,609,000, indicating a continued burn rate that consumes cash reserves to fund ongoing clinical trials and platform development. Analysis of the three primary margins confirms the pre-profitability status: the Gross Margin stands at 0.0%, the Operating Margin is 0.0%, and the Profit Margin is 0.0%, reflecting that no revenue has been generated to support gross profit or operational earnings yet. Regarding liquidity and leverage, the firm holds Cash of $44.79M against total Debt of $14.77M, resulting in a Debt to Equity ratio of 56.85, which suggests a levered balance sheet common in biotech but requiring careful cash management. The Current Ratio is reported at 2.07, indicating that the company holds sufficient current assets to cover its short-term liabilities, providing a layer of financial stability despite the operating losses. Return on Equity is -145.7% and Return on Assets is -61.0%, metrics that reveal the aggressive dilution or capital deployment typical of early-stage development companies where losses directly impact the book value of equity and asset efficiency.
Avaliação de valorização
The company presents a Trailing P/E Ratio (TTM) of N/A and a Forward P/E of -2.77, the latter being negative due to the reported losses which preclude a standard earnings-based valuation multiple. The absence of a trailing P/E implies that traditional earnings-based valuation models are currently inapplicable, while the negative forward P/E signals that the market prices the stock based on future potential rather than current profitability. The Price to Book ratio is 3.56, indicating that the market values the company at a significant premium over its tangible book value, a common occurrence for biotech firms with valuable intellectual property that is not fully reflected on the balance sheet. Since Revenue (TTM) is N/A, a Price to Sales ratio is also N/A, and the EV/EBITDA stands at -1.93, these alternative metrics further underscore that valuation is driven by pipeline potential rather than historical financial performance. The stock has traded between a 52-Week High of $2.66 and a 52-Week Low of $0.40, and without the specific current share price to calculate the exact percentage deviation, the range demonstrates a wide volatility band typical for small-cap biotechnology stocks. The Beta is 0.50, suggesting that the stock's price volatility is significantly lower than the broader market, moving with less intensity than large-cap equities despite the inherent risks of the biotech sector.
Growth & Income
Revenue Growth (YoY) is N/A and Earnings Growth (YoY) is N/A, as the company has not yet achieved commercial sales to generate comparable historical data for year-over-year analysis. Consequently, the company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning that any available cash is theoretically reinvested into growth initiatives rather than distributed to shareholders. The absence of a dividend yield aligns with the strategy of clinical-stage biotechnology firms that prioritize funding their drug development programs over returning capital to investors. The overall growth and income profile is characterized by a lack of current earnings growth and a complete absence of dividend income, relying entirely on the successful progression of its lead product candidate, Evorpacept, to future profitability.